MacuLogix
MacuLogix developed the AdaptDx Pro, a diagnostic device that measures dark adaptation to detect early-stage age-related macular degeneration, serving ophthalmologists, optometrists, and retina specialists in the U.S. eye care market. The company was acquired by LumiThera Diagnostics in 2025.
- Company typePrivate
- Founded2004
- HeadquartersHarrisburg, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
MacuLogix firmographics
Firmographics- Name
- MacuLogix
- Website
- https://maculogix.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- MacuLogix developed the AdaptDx Pro, a diagnostic device that measures dark adaptation to detect early-stage age-related macular degeneration, serving ophthalmologists, optometrists, and retina specialists in the U.S. eye care market. The company was acquired by LumiThera Diagnostics in 2025.
- Ownership category
- akta.pro rank
MacuLogix industry classification
Industry- Product category
- Ophthalmic Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Ophthalmic Goods Manufacturing (339115)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)
Keywords
Where MacuLogix is headquartered
LocationHeadquarters
- HQ city
- Harrisburg
- HQ country
- United States
- HQ region
- North America
Markets served
MacuLogix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
MacuLogix product offering
Product offeringCore offering
MacuLogix develops and sells the AdaptDx Pro, a dark adaptation testing device that measures how quickly a patient's eyes adapt to darkness to detect and monitor age-related macular degeneration (AMD). The product is sold to eye care professionals including ophthalmologists, optometrists, and retina specialists for non-invasive screening and monitoring of retinal function. The product line was acquired by LumiThera Diagnostics in 2025.
Differentiator
Problem solved
Functional benefit
Companies that use MacuLogix
Customer profileSegments1 record
Ideal customer profiles1 record
MacuLogix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
MacuLogix partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LumiThera DiagnosticsflagshipLumiThera Diagnostics acquired MacuLogix in 2025, absorbing the AdaptDx product line and decommissioning the MacuLogix website. The AdaptDx Pro technology is now integrated into LumiThera's diagnostic portfolio for eye care.
MacuLogix competitors and assessment
Company assessmentDirect peers
- Optos (Nikon Healthcare): Specialist in ultra-widefield retinal imaging used by ophthalmologists and optometrists for AMD and diabetic retinopathy screening. Directly comparable as a retinal diagnostic vendor competing for in-office diagnostic capital in the same AMD care pathway.
- CenterVue (iCare): Specialist in retinal imaging and visual field diagnostics for ophthalmic professionals. Comparable as a focused ophthalmic diagnostic equipment company with overlapping product categories used in AMD and glaucoma assessment.
- Heidelberg Engineering: Developer and manufacturer of ophthalmic diagnostic imaging systems (OCT, confocal microscopy) widely used in retina and glaucoma practices. Directly comparable as a specialist ophthalmic diagnostic equipment vendor serving the same eye-care professional customer base that buys AdaptDx Pro.
- Notal Vision: Provider of home-based AMD monitoring (ForeseeHome) and related diagnostic services for retina specialists. Directly comparable as a company focused on AMD detection and monitoring, addressing the same patient population and clinical decision points as AdaptDx Pro.
Others
- LumiThera: Parent acquirer of MacuLogix and developer of photobiomodulation devices for ophthalmic conditions. Comparable as the strategic acquirer that now controls AdaptDx Pro commercialization, and as an adjacent player in the AMD therapeutic and diagnostic continuum.
Broad incumbents
- Carl Zeiss Meditec: Large incumbent ophthalmic device company offering diagnostic imaging, surgical microscopy, and laser systems to retina and refractive specialists. Comparable as a broad ophthalmic diagnostics incumbent whose products are integrated alongside AdaptDx Pro in retina practices.
- Nidek: Manufacturer of ophthalmic diagnostic and surgical equipment including OCT and fundus imaging. Comparable as a long-established diagnostic vendor whose retinal imaging products are part of the AMD diagnostic workflow.
- Topcon Healthcare: Diversified ophthalmic equipment manufacturer offering OCT, fundus cameras, and diagnostic devices. Comparable as an incumbent diagnostic equipment vendor serving optometry and ophthalmology channels with overlapping AMD-relevant instrumentation.
Regional players
- Kowa Optimed: Manufacturer of ophthalmic diagnostic imaging systems including retinal cameras used in screening and monitoring of AMD. Comparable as an ophthalmic diagnostic equipment vendor with overlapping AMD-relevant imaging offerings.
Emerging players
- Revenio Group (iCare / Optomed): Ophthalmic device group with handheld fundus imaging and screening devices targeting primary care and optometry channels. Comparable as an emerging vendor expanding diagnostic access for retinal disease screening, including AMD, in non-specialist settings.
Market position
Customer concentration
MacuLogix social profiles
Digital presenceMacuLogix financial estimates
Financial estimateRevenue estimate
Valuation estimate
MacuLogix leadership team
Management profileNumber of profiles
Profiles3 records
MacuLogix funding detail
Funding detailFunding overview
Funding rounds7 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MacuLogix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MacuLogix
What does MacuLogix do?
MacuLogix develops and sells the AdaptDx Pro, a dark adaptation testing device that measures how quickly a patient's eyes adapt to darkness to detect and monitor age-related macular degeneration (AMD). The product is sold to eye care professionals including ophthalmologists, optometrists, and retina specialists for non-invasive screening and monitoring of retinal function. The product line was acquired by LumiThera Diagnostics in 2025.
When was MacuLogix founded?
MacuLogix was founded in 2004. It employs 101 to 250 people.
Where is MacuLogix based?
MacuLogix is headquartered in Harrisburg, United States, in the North America region.
Who are MacuLogix's main competitors?
Direct peers on record are Optos (Nikon Healthcare), CenterVue (iCare), Heidelberg Engineering and Notal Vision. LumiThera is listed as an others. Broad incumbents are Carl Zeiss Meditec, Nidek and Topcon Healthcare. Kowa Optimed is listed as a regional player. Revenio Group (iCare / Optomed) is listed as an emerging player.
Does MacuLogix have an API?
No public API is recorded for MacuLogix.
What industry is MacuLogix in?
MacuLogix's product category is Ophthalmic Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity). Its NAICS code is 334510 and its SIC code is 3841.